Biotech · Private company · Cupertino, CA, US
Durect Corp
SEC CIK 0001082038
Track this companyFree. Adds Durect Corp to your Dealase workspace and tells you when its record changes.
Clinical trials91 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- Bupivacaine HClPhase 3 · Post Operative PainClinicalTrials.gov · fetched Nov 12, 2026
- Bupivacaine HClPhase 3 · Postoperative PainClinicalTrials.gov · fetched Nov 12, 2026
- SABER-BupivacainePhase 3 · Postoperative PainClinicalTrials.gov · fetched Nov 12, 2026
- SABER-Bupivacaine (Part 1)Phase 3 · Post Operative PainClinicalTrials.gov · fetched Nov 12, 2026
- SABER-Bupivacaine (Part 2)Phase 3 · Post Operative PainClinicalTrials.gov · fetched Nov 12, 2026
- Bupivacaine TTS (Bupivacaine Patch)Phase 2 · Chronic Low Back PainClinicalTrials.gov · fetched Nov 12, 2026
- DUR-928Phase 2 · Primary Sclerosing CholangitisClinicalTrials.gov · fetched Nov 12, 2026
- DUR-928Phase 2 · SARS-CoV-2ClinicalTrials.gov · fetched Nov 12, 2026
- DUR-928 150 mgPhase 2 · Alcoholic HepatitisClinicalTrials.gov · fetched Nov 12, 2026
- DUR-928 30 mgPhase 2 · Alcoholic HepatitisClinicalTrials.gov · fetched Nov 12, 2026
- DUR-928 90 mgPhase 2 · Alcoholic HepatitisClinicalTrials.gov · fetched Nov 12, 2026
- DUR-928 Topical SolutionPhase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle Topical SolutionPhase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)PHASE3 · RECRUITING · started Jan 29, 2026ClinicalTrials.gov NCT07428538 · fetched Nov 12, 2026
- A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentPHASE2 · COMPLETED · started Jan 22, 2021ClinicalTrials.gov NCT04563026 · fetched Nov 12, 2026
- DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney InjuryPHASE2 · TERMINATED · started Sep 21, 2020ClinicalTrials.gov NCT04447404 · fetched Nov 12, 2026
- Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque PsoriasisPHASE2 · COMPLETED · started Feb 21, 2019ClinicalTrials.gov NCT03837743 · fetched Nov 12, 2026
- A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic HepatitisPHASE2 · COMPLETED · started Apr 18, 2018ClinicalTrials.gov NCT03432260 · fetched Nov 12, 2026
- A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)PHASE2 · TERMINATED · started Jan 22, 2018ClinicalTrials.gov NCT03394781 · fetched Nov 12, 2026
- Trial of Extended Release Bupivacaine for Pain Relief After SurgeryPHASE3 · COMPLETED · started Nov 1, 2015ClinicalTrials.gov NCT02574520 · fetched Nov 12, 2026
- Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back PainPHASE2 · COMPLETED · started Mar 1, 2010ClinicalTrials.gov NCT01096966 · fetched Nov 12, 2026
- Bupivacaine Effectiveness and Safety in SABER® TrialPHASE3 · COMPLETED · started Dec 1, 2009ClinicalTrials.gov NCT01052012 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Sep 11, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 12, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 8, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 29, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 11, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 13, 2025 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 27, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 26, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 21, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 28, 2025 · fetched Nov 12, 2026